| Purpose of the guideline: |
Primary lung cancer, which leads in both incidence and mortality rates among all malignant tumors in China, ranks first in fatalities caused by malignant diseases. Given the lung's rich blood supply, distant metastases of lung cancer are common, with the brain being a frequent site for such metastasis.
Patients with brain metastases from lung cancer have a poor prognosis, with a natural median survival time of only 1 to 2 months. However, the rapid development of surgical procedures, radiotherapy techniques, and medical treatments has increasingly diversified treatment options for these patients. The treatment level for stage IV primary lung cancer in China has been continuously improving, enhancing the quality of life and extending the survival time for patients with brain metastases from lung cancer.
To further standardize the treatment of patients with brain metastases from lung cancer in China, Professors Zhi-Xiu Yi and Jie Wang have spearheaded the development of the "Chinese Guidelines for Managing Brain Metastases in Non-Small Cell Lung Cancer with Actionable Driver Mutation (2025 Edition) " aiming to comprehensively improve the survival prognosis of these patients. |
